Chisa Nakashima

Chisa Nakashima

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
CNChisa Nakashima
Chisa Nakashima
AOAtsushi Otsuka
Atsushi Otsuka
KKKenji Kabashima
Kenji Kabashima

25 March 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
YYYuto Yamamura
Yuto Yamamura
CNChisa Nakashima
Chisa Nakashima
AOAtsushi Otsuka
Atsushi Otsuka
The pathogenesis of atopic dermatitis (AD) is understood to be crucially influenced by three main factors: dysregulation of the immune response, barrier dysfunction, and pruritus. In the lesional skin of AD, various innate immune cells, including Th2 cells, type 2 innate lymphoid cells (ILC2s), and basophils, produce Th2 cytokines [interleukin (IL)-4, IL-5, IL-13, IL-31]. Alarmins such as TSLP, IL-25, and IL-33 are also produced by epidermal keratinocytes, amplifying type 2 inflammation. In the chronic phase, not only Th2 cells but also Th22 and Th17 cells increase in number, leading to suppression of filaggrin expression by IL-4, IL-13, and IL-22, which further deteriorates the epidermal barrier function. Dupilumab, which targets IL-4 and IL-13, has shown efficacy in treating moderate to severe AD. Nemolizumab, targeting IL-31RA, effectively reduces pruritus in AD patients. In addition, clinical trials with fezakinumab, targeting IL-22, have demonstrated promising results, particularly in severe AD cases. Conversely, in murine models of AD, several cytokines, initially regarded as promising therapeutic targets, have not demonstrated sufficient efficacy in clinical trials. IL-33 has been identified as a potent activator of immune cells, exacerbating AD in murine models and correlating with disease severity in human patients. However, treatments targeting IL-33 have not shown sufficient efficacy in clinical trials. Similarly, thymic stromal lymphopoietin (TSLP), integral to type 2 immune responses, induces dermatitis in animal models and is elevated in human AD, yet clinical treatments like tezepelumab exhibit limited efficacy. Therapies targeting IL-1α, IL-5, and IL-17 also failed to achieve sufficient efficacy in clinical trials. It has become clear that for treating AD, IL-4, IL-13, and IL-31 are relevant therapeutic targets during the acute phase, while IL-22 emerges as a target in more severe cases. This delineation underscores the necessity of considering distinct pathophysiological aspects and therapeutic targets in AD between mouse models and humans. Consequently, this review delineates the distinct roles of cytokines in the pathogenesis of AD, juxtaposing their significance in human AD from clinical trials against insights gleaned from AD mouse models. This approach will improve our understanding of interspecies variation and facilitate a deeper insight into the pathogenesis of AD in humans.

13 January 2023 in The Journal of Dermatology
Verified
Journal Article
Open access
CNChisa Nakashima
Chisa Nakashima
MKMaiko Kato
Maiko Kato
AOAtsushi Otsuka
Atsushi Otsuka
In December 2019, a new infectious pathogen named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in Wuhan, China. Transmitted through respiratory droplets, SARS‐CoV‐2 is the causative pathogen of coronavirus disease 2019 (COVID‐19). Although this new COVID‐19 infection is known to cause primarily interstitial pneumonia and respiratory failure, it is often associated with cutaneous manifestations as well. These manifestations with COVID‐19 can be classified into seven categories: (i) chilblain‐like skin eruption (e.g., COVID toes), (ii) urticaria‐like skin eruption, (iii) maculopapular lesions, (iv) vesicular eruptions, (v) purpura, (vi) livedo reticularis and necrotic lesions, (vii) urticarial vasculitis, and others such as alopecia and herpes zoster. The pathogenesis of skin eruptions can be broadly divided into vasculitic and inflammatory skin eruptions. Various cutaneous adverse reactions have also been observed after COVID‐19 mRNA vaccination. The major cutaneous adverse reactions are type I hypersensitivity (urticaria and anaphylaxis) and type IV hypersensitivity (COVID arm and erythema multiform). Autoimmune‐mediated reactions including bullous pemphigus, vasculitis, vitiligo, and alopecia areata have also been reported. Several cases with chilblain‐like lesions and herpes zoster after COVID‐19 mRNA vaccination have been published. Various skin diseases associated with COVID‐19 and COVID‐19 vaccination have been reported, and the mechanism has been partly elucidated. In the process, for example, some papers have reported that it is not related to COVID‐19 infection, although it was initially called COVID‐toe and considered a COVID‐19‐associated cutaneous eruption. In fact, some COVID‐19‐associated skin reactions are indistinguishable from drug eruptions. In the future, the mechanisms of COVID‐19‐ or COVID‐19 vaccine‐associated skin reactions need to be elucidated and verification of causal relationships is required.

30 November 2023 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KUKenji Usui
Kenji Usui
CNChisa Nakashima
Chisa Nakashima
STSonoko Takahashi
Sonoko Takahashi
TOTakaharu Okada
Takaharu Okada
YIYoshihiro Ishida
Yoshihiro Ishida
KKKenji Kabashima
Kenji Kabashima

1 September 2015 in Journal of Dermatological Science
Verified
Journal Article
Closed access
HTHideaki Tanizaki
Hideaki Tanizaki
CNChisa Nakashima
Chisa Nakashima
CSChihiro Shimizuhira
Chihiro Shimizuhira
YMYoshiki Miyachi
Yoshiki Miyachi
KKKenji Kabashima
Kenji Kabashima

19 July 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CNChisa Nakashima
Chisa Nakashima
YIY. Ishida
Y. Ishida
YKY. Kaku
Y. Kaku
EEE.H. Epstein
E.H. Epstein
AOAtsushi Otsuka
Atsushi Otsuka
KKKenji Kabashima
Kenji Kabashima